KBC Group NV Sells 2,633 Shares of Alexion Pharmaceuticals, Inc. (ALXN)

KBC Group NV cut its stake in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 9.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 26,549 shares of the biopharmaceutical company’s stock after selling 2,633 shares during the period. KBC Group NV’s holdings in Alexion Pharmaceuticals were worth $3,725,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently modified their holdings of ALXN. Fiduciary Trust Co. purchased a new stake in shares of Alexion Pharmaceuticals in the second quarter worth approximately $111,000. Dupont Capital Management Corp purchased a new stake in shares of Alexion Pharmaceuticals in the third quarter worth approximately $156,000. BT Investment Management Ltd purchased a new stake in shares of Alexion Pharmaceuticals in the third quarter worth approximately $165,000. Penserra Capital Management LLC raised its holdings in shares of Alexion Pharmaceuticals by 13.0% in the second quarter. Penserra Capital Management LLC now owns 1,248 shares of the biopharmaceutical company’s stock worth $151,000 after buying an additional 144 shares during the period. Finally, Acadian Asset Management LLC purchased a new stake in shares of Alexion Pharmaceuticals in the second quarter worth approximately $160,000. Institutional investors and hedge funds own 94.16% of the company’s stock.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) opened at $106.78 on Friday. Alexion Pharmaceuticals, Inc. has a 52 week low of $96.18 and a 52 week high of $149.34. The stock has a market capitalization of $23,930.00, a P/E ratio of 22.27, a P/E/G ratio of 1.18 and a beta of 1.18. The company has a quick ratio of 2.51, a current ratio of 2.96 and a debt-to-equity ratio of 0.35.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.32 by $0.12. The business had revenue of $859.00 million for the quarter, compared to analysts’ expectations of $864.34 million. Alexion Pharmaceuticals had a return on equity of 12.55% and a net margin of 14.57%. The business’s revenue for the quarter was up 7.5% on a year-over-year basis. During the same quarter last year, the firm earned $1.23 EPS. analysts expect that Alexion Pharmaceuticals, Inc. will post 4.82 EPS for the current year.

ALXN has been the topic of several recent analyst reports. BidaskClub downgraded Alexion Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, August 14th. Evercore ISI initiated coverage on Alexion Pharmaceuticals in a report on Wednesday, August 16th. They issued an “in-line” rating and a $137.00 price target on the stock. J P Morgan Chase & Co upgraded Alexion Pharmaceuticals from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $163.00 to $175.00 in a report on Tuesday, September 5th. BMO Capital Markets reiterated an “outperform” rating and issued a $173.00 price target (up from $168.00) on shares of Alexion Pharmaceuticals in a report on Wednesday, September 13th. Finally, SunTrust Banks reiterated a “buy” rating and issued a $180.00 price target (up from $170.00) on shares of Alexion Pharmaceuticals in a report on Wednesday, September 13th. Five investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $154.49.

COPYRIGHT VIOLATION WARNING: “KBC Group NV Sells 2,633 Shares of Alexion Pharmaceuticals, Inc. (ALXN)” was published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this story on another site, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.chaffeybreeze.com/2017/12/08/kbc-group-nv-sells-2633-shares-of-alexion-pharmaceuticals-inc-alxn.html.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply